• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NeuroPace touts 8-year brain-responsive neurostim trial data

NeuroPace touts 8-year brain-responsive neurostim trial data

December 5, 2017 By Fink Densford

NeuroPaceNeuroPace today released eight-year prospective clinical study data from trials of its closed-loop brain-responsive neurostimulation system, touting a 73% median seizure reduction among patients.

Data from the trials was presented at the American Epilepsy Society’s annual meeting in Washington D.C. this week, the Mountain View, Calif.-based company said.

The data came from 256 adult patients across feasibility trials, pivotal trials and long-term treatment trials and represented 1,825 implant years and an average follow-up of 8.1 years, NeuroPace said.

Results indicated a 73% median rate of seizure reduction at the eighth year, NeuroPace said, with a 90% seizure reduction rate or better in 30% of patients in the most recent three months. Seizure-free periods lasting one year or more were also experienced in 18% of patients, the company reported.

“In addition to compelling therapeutic benefits, the RNS System is the only device that provides information about a patient’s brain activity over months and years. With over 1.5 million stored brain recordings, the unprecedented data from the RNS System is helping us advance science. It is fueling research on seizure biomarkers, seizure forecasting, effects on memory, and possible synergies between specific antiepileptic medication and neuromodulation. We are optimistic that the clinical insights gained from this large body of data will continue to help clinicians improve their patients’ outcomes,” NeuroPace chief medical officer Dr. Martha Morrell said in a prepared statement.

In October, NeuroPace said it raised a $74 million funding round, saying it plans to use the infusion to speed the commercialization of its implantable neurostimulation device for treating epilepsy.

Filed Under: Clinical Trials, Neuromodulation/Neurostimulation Tagged With: NeuroPace

More recent news

  • Mount Sinai adopts Flosonics wearable ultrasound device
  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy